Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 186

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Atopic keratoconjunctivitis

Not recruiting

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Dompe' Farmaceutici S.p.A.

Immunoglobulin G4 related disease

Not recruiting

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Small cell lung cancer extensive stage

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Hypophosphatasia

Not recruiting

Study on ALXN1850 for Adolescents and Adults with Hypophosphatasia Not Previously Treated with Asfotase Alfa

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALXN1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Transitional cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not recruiting

Study on the Effects of VH4524184 for Adults Newly Diagnosed with HIV

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VH4524184
  • Sponsor:Viiv Healthcare UK Limited

Hepatic cirrhosis

Not recruiting

Study on the Safety of Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Astrazeneca AB

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Astrazeneca AB

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.